AVR

4.08%

$12.49 anteris technologies ltd

Well done fox that post deserved to stay. Thanks to Wpaul for...

First 15 Last

Share
Profile

Follow
ecrawf

311 Posts.

05/09/14

14:26

Post #: 13931262
Share

Originally posted by silverfox3731 ↑

Here below Wpauls great post that got moderated..

I kept it and the one by Quacker as they are a great resource when it comes to undestanding the interim phase 2 trial results in coming months. My comment is that gennocea have set the benchmark with just over a 50% reduction in the frequency of Flairs. Hopefully AHZ can get a 100% reduction but 70 to 80% will be outstanding.

Great to be able to see the views of Julian Chick in Quackers post and welcome WPaul. Your scientific input will be most valuable.

Wpaul post hsv 5 sep.......... "My first time posting and actually the first shares that I ever purchased, so be gentle. I feel like I can shed a little light on the science aspect of vaccines, I’m a published scientific author in HIV vaccines. A therapeutic vaccine doesn't necessarily have to be curative to be therapeutic it can just mediate the virus not necessarily kill it. This is an important distinction particularly when refereeing to herpes viruses as herpes viruses infects nerve cells. The goal of the vaccine was to induce both antibody and T cell responses and the interim results already released stated that only T cells were being generated and hence the definition of therapeutic vaccine. Antibodies can provide protection prior to the virus infecting any cells and is the most important part of a prophylactic vaccine. T cells work by killing the virus infected cell, with herpes infecting nerve cells, you don’t necessarily want to kill the cell or you will have never damage and potentially very server outcomes. Interesting studies in Herpes simplex 1 (not what AHZ have been working on) showed that T cell response didn’t kill the virus but prevented the virus from killing the nerve cells. I believe this is what the therapeutic HSV-2 vaccine is based on is meditating the symptoms and consequently inhibiting the spread of the virus. A therapeutic vaccine may present even better investment opportunities as well as there is the very real potential that it will need to be given multiple times. I personally like the regenerative technology they have and continue to develop which has a lot of potential for future uses. "

Fox

Expand

Well done fox that post deserved to stay. Thanks to Wpaul for posting.

AHZ Price at posting: 15.2¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

4DX

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

ZER

Zeta Resources seeks to resolve the Panoramic takeover story

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

There are more pages in this discussion • 7 more messages in this thread...

First 15 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $12.49		Change 0.490(4.08%)		Mkt cap ! $264.0M

Open	High	Low	Value	Volume
$12.11	$12.49	$11.50	$155.8K	13.16K

Buyers (Bids)

No.	Vol.	Price($)
1	175	$11.81

Sellers (Offers)

Price($)	Vol.	No.
$12.49	77	1

View Market Depth

No.	Vol.	Price($)
1	175	11.810
1	150	11.800
2	772	11.600
2	2000	11.500
1	80	11.250

Price($)	Vol.	No.
12.490	77	1
12.500	56	1
12.520	500	1
12.850	99	1
13.000	2000	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

AVR (ASX) Chart

Well done fox that post deserved to stay. Thanks to Wpaul for...

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Well done fox that post deserved to stay. Thanks to Wpaul for...

Top Stories

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The market's shrugged at China's stimulus measures all year. Why is this one different?

4DMedical lands Philips US reseller deal with eye to Veterans Affairs' market post-lung damage

Zeta Resources seeks to resolve the Panoramic takeover story

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before its acquisition of Namoi Cotton can go ahead

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News